Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line tislelizumab plus gemcitabine in cisplatin-ineligible advanced urothelial cancer
ChiCTR2200061631Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and gemcitabine in transitional cell carcinoma (TCC), sponsored by Shandong Cancer Hospital. Primary endpoints: Objective response rate and Disease control rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
tislelizumabgemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2200061631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061631.